$-0.06 EPS Expected for Diffusion Pharmaceuticals Inc. (DFFN)

July 14, 2018 - By Margaret Guttierez

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Logo

Analysts expect Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) to report $-0.06 EPS on August, 13.They anticipate $0.94 EPS change or 94.00 % from last quarter’s $-1 EPS. After having $-0.27 EPS previously, Diffusion Pharmaceuticals Inc.’s analysts see -77.78 % EPS growth. The stock decreased 2.85% or $0.0134 during the last trading session, reaching $0.4566. About 135,551 shares traded. Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has declined 81.45% since July 14, 2017 and is downtrending. It has underperformed by 94.02% the S&P500.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The company has market cap of $23.07 million. The Company’s lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme ; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. It currently has negative earnings. The firm is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.